(Q33299767)

25 July 2017

title

A new therapy for highly effective tumor eradication using HVJ-E combined with chemotherapy (English)

1 reference

25 July 2017

1 reference

Hirokazu Kawano

1

1 reference

25 July 2017

Shintarou Komaba

series ordinal

2

1 reference

25 July 2017

Toshihide Kanamori

series ordinal

3

1 reference

25 July 2017

Yasufumi Kaneda

series ordinal

4

1 reference

25 July 2017

language of work or name

English

0 references

publication date

21 September 2007

1 reference

25 July 2017

1 reference

25 July 2017

volume

5

1 reference

25 July 2017

page(s)

28

1 reference

New potential therapy for orthotopic bladder carcinoma by combining HVJ envelope with doxorubicin

25 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2039728

Targeted chemotherapy against intraperitoneally disseminated colon carcinoma using a cationized gelatin-conjugated HVJ envelope vector

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2039728

Rad51 siRNA delivered by HVJ envelope vector enhances the anti-cancer effect of cisplatin.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2039728

Cancer immunotherapy: a treatment for the masses

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2039728

Immunotherapy: bewitched, bothered, and bewildered no more

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2039728

Escape from immunotherapy: possible mechanisms that influence tumor regression/progression.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2039728

Immunotherapy and immunoselection -- tumour escape as the final hurdle

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2039728

Molecular targeting of drug delivery systems to cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2039728

Drug delivery systems: entering the mainstream

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2039728

Replication of an E1B 55-kilodalton protein-deficient adenovirus (ONYX-015) is restored by gain-of-function rather than loss-of-function p53 mutants

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2039728

Cancer-specific viruses and the development of ONYX-015

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2039728

Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2039728

RNA viruses as virotherapy agents

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2039728

Hemagglutinating virus of Japan (HVJ) envelope vector as a versatile gene delivery system

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2039728

Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2039728

Induction of antigen-specific T cell anergy: An early event in the course of tumor progression

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2039728

Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2039728

Can cancer chemotherapy enhance the malignant behaviour of tumours?

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2039728

ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents

21 June 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-5-28

Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-5-28

Adjuvant, adoptive immunotherapy with tumor infiltrating lymphocytes plus interleukin-2 after radical hepatic resection for colorectal liver metastases: 5-year analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-5-28

Randomized trial of adjuvant therapy in colon carcinoma: 10-year results of NSABP protocol C-01.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-5-28

Intratumoral injection of inactivated Sendai virus particles elicits strong antitumor activity by enhancing local CXCL10 expression and systemic NK cell activation

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2039728

CD4(+) and CD8(+) anergic T cells induced by interleukin-10-treated human dendritic cells display antigen-specific suppressor activity

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2039728

Tumour-induced suppression of immune response and its correction

31 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/17883878

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/17883878

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/1741-7015-5-28

1 reference

Dimensions Publication ID

25 July 2017

0 references

1 reference

25 July 2017

1 reference